<p>Structures of TIE-2 inhibitors compound <b>1</b>–<b>4</b>.</p> Full article ">Figure 2
<p>The dose–response activity of the three TIE-2 inhibitors from the Merck Mini Library. The results from the primary screening are displayed in (<b>A</b>) against HAdV and (<b>B</b>) against RVFV in A549 cells. Ñ = visual compound precipitation; * = visual host cell toxicity. (<b>C</b>) Activity against SARS-CoV-2 in VeroE6 cells using plaque reduction assay. * = visual host cell toxicity.</p> Full article ">Figure 3
<p>The dose–response antiviral activity of compounds <b>1</b> and <b>4</b> (<a href="#viruses-17-00385-f001" class="html-fig">Figure 1</a>) and remdesivir as a positive control against SARS-CoV-2 in Hela3ACE2 cells. Graphs show antiviral activity measured with a SARS-CoV-2 immunofluorescence signal leading to identification of infected cells with 0% activity equals 100% infected cells (blue curve), total cells per well in SARS-CoV-2 infected cell test with 0% activity equaling no change vs. control (yellow curve), total cells per well in HeLa-ACE2 uninfected cell control (red curve).</p> Full article ">Figure 4
<p>Dose–response antiviral activity against SARS-CoV-2 of compound <b>4</b> (<a href="#viruses-17-00385-f001" class="html-fig">Figure 1</a>) and remdesivir as a positive control in Calu3 cells. The graphs show antiviral activity measured with a SARS-CoV-2 immunofluorescence signal, leading to the identification of infected cells with 0% activity equaling 100% infected cells (green curve), total cells per well in the SARS-CoV-2 infected cell test with 0% activity equaling no change vs. the control (yellow curve), and total cells per well in the HeLa-ACE2 uninfected cell control (red curve).</p> Full article ">Figure 5
<p>Antiviral activity dose response curves for compound <b>1</b> and compound <b>4</b> against HAdV, dengue virus, and influenza virus.</p> Full article ">Figure 6
<p>Activity in human primary mucociliary airway stem cell-based SARS-CoV-2 infection model for compound <b>4</b> compared to remdesivir and molnupiravir tested at 10 µM.</p> Full article ">Figure 7
<p>In vivo antiviral efficacy of compound <b>4</b> against SARS-CoV-2. Mice exhibited increased survival (<b>A</b>), reduced body weight loss (<b>B</b>), and reduced viral load in lungs (<b>C</b>) after oral treatment b.i.d. with 60 mg/kg compound 4 in 0.5% methocel/0.25% Tween-20/water in comparison to placebo. EIDD-2801 (molnupiravir) dosed same way was used as positive control. (ns <span class="html-italic">p</span> > 0.05, * <span class="html-italic">p</span> ≤ 0.05, ** <span class="html-italic">p</span> ≤ 0.01, *** <span class="html-italic">p</span> ≤ 0.001).</p> Full article ">